These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21777190)

  • 1. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic.
    Spear MA; LoRusso P; Mita A; Mita M
    Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular-disrupting agents in oncology.
    Mita MM; Sargsyan L; Mita AC; Spear M
    Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular disrupting agents: a new class of drug in cancer therapy.
    Gaya AM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):277-90. PubMed ID: 15997924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVE8062: a new combretastatin derivative vascular disrupting agent.
    Delmonte A; Sessa C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.
    Cooney MM; van Heeckeren W; Bhakta S; Ortiz J; Remick SC
    Nat Clin Pract Oncol; 2006 Dec; 3(12):682-92. PubMed ID: 17139319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development and use of vascular targeted therapy in ovarian cancer.
    Chase DM; Chaplin DJ; Monk BJ
    Gynecol Oncol; 2017 May; 145(2):393-406. PubMed ID: 28238563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular toxicity profiles of vascular-disrupting agents.
    Subbiah IM; Lenihan DJ; Tsimberidou AM
    Oncologist; 2011; 16(8):1120-30. PubMed ID: 21742963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular disrupting agents (VDAs) in anticancer therapy.
    Daenen LG; Roodhart JM; Shaked Y; Voest EE
    Curr Clin Pharmacol; 2010 Aug; 5(3):178-85. PubMed ID: 20406172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments.
    Ji YT; Liu YN; Liu ZP
    Curr Med Chem; 2015; 22(11):1348-60. PubMed ID: 25620094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vascular disrupting agents and ionizing radiation.
    Clémenson C; Chargari C; Deutsch E
    Crit Rev Oncol Hematol; 2013 May; 86(2):143-60. PubMed ID: 23177097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular disrupting agents in clinical development.
    Hinnen P; Eskens FA
    Br J Cancer; 2007 Apr; 96(8):1159-65. PubMed ID: 17375046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises.
    Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG
    Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting tumour blood vessels.
    Tozer GM; Kanthou C; Baguley BC
    Nat Rev Cancer; 2005 Jun; 5(6):423-35. PubMed ID: 15928673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
    Close A
    Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies.
    Kanthou C; Tozer GM
    Int J Exp Pathol; 2009 Jun; 90(3):284-94. PubMed ID: 19563611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.
    Chen M; Lei X; Shi C; Huang M; Li X; Wu B; Li Z; Han W; Du B; Hu J; Nie Q; Mai W; Ma N; Xu N; Zhang X; Fan C; Hong A; Xia M; Luo L; Ma A; Li H; Yu Q; Chen H; Zhang D; Ye W
    J Clin Invest; 2017 Oct; 127(10):3689-3701. PubMed ID: 28846068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.
    Mason RP; Zhao D; Liu L; Trawick ML; Pinney KG
    Integr Biol (Camb); 2011 Apr; 3(4):375-87. PubMed ID: 21321746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.